Infinity Bio, a biotechnology company pioneering large-scale immune response mapping technologies, announced the successful completion of an $8 million Series A financing round led by Illumina Ventures. The funding round included participation from PTX Capital, Blackbird BioVentures, and Propel Baltimore Fund, positioning the company to accelerate development of its proprietary antibody reactome profiling platform.
Strategic Acquisition and Platform Expansion
As part of its growth strategy, Infinity Bio acquired the assets of Serimmune, Inc., a company founded in 2014 that specialized in providing unbiased antibody reactome services. This acquisition is designed to broaden Infinity Bio's suite of service offerings and enhance its technological capabilities in immune profiling.
The company plans to launch new MIPSA™ service offerings, including EnviroSIGHT™, in the second half of 2025. These additions will complement the existing portfolio of core services including HuSIGHT™, VirSIGHT™, AllerSIGHT™, and MuSIGHT™, which are designed to support applications in biomarker discovery, basic and translational research, and therapeutic development.
MIPSA™ Platform Technology
Infinity Bio's core technology, MIPSA™, enables comprehensive analysis of the antibody reactome, revealing the targets of individual immune responses against all known human viruses, human proteins associated with autoimmunity, and allergen proteins. The platform was developed at Johns Hopkins University in The Laboratory of Precision Immunology and builds on decades of work in genomics, proteomics, immunology, and bioinformatics.
"True to our name, Infinity Bio is building a limitless capacity to generate high quality antibody reactome data and deliver valuable biological insights for just about any kind of study," said Ben Larman, Chief Science Officer of Infinity Bio and associate professor of pathology at Johns Hopkins University. "Our technologies illuminate the complex interplay between inflammation, immunity, and health."
Commercial Operations and Capacity
Since its founding in 2023, Infinity Bio has established a 9,000 square-foot laboratory facility in Baltimore. The company's platform is capable of processing thousands of samples per week, serving academic institutions, government agencies, and biopharmaceutical companies. The assays are engineered to deliver best-in-class quality, data accuracy, turnaround times, and cost-efficiency.
"This raise marks a major milestone for Infinity Bio," said Joy Nassif, Chief Executive Officer. "We are building the foundation for a new category of immune system intelligence: accessible, scalable, and deeply informative. With support from our investors, we can now move faster to deliver that vision."
Investor Perspective and Market Positioning
The investment from Illumina Ventures reflects confidence in the platform's potential to transform biomedical research capabilities. "We applaud the scientific prowess of Infinity Bio to provide insights into the immune system through its antibody reactome profiling platform," said Malek Faham, MD, PhD, Chief Scientist at Illumina Ventures. "Combined with the assets from Serimmune, this enhanced, more comprehensive technology is a game changer for biomedical researchers who can use it for a broad range of applications to accelerate their discoveries."
Matt Hellauer, Managing Partner at PTX Capital and Chairman of Infinity Bio, emphasized the company's strategic positioning: "We launched Infinity Bio with global ambition to unlock a new layer of immune system data that drives better diagnostics, targeted therapies, and deeper disease insight. Partnering with a world-class firm like Illumina Ventures reinforces that vision and positions Infinity to scale as the category leader in antibody reactome profiling."
The funding will support Infinity Bio's plans to expand its commercial footprint, accelerate development of the MIPSA™ platform, and launch new immune profiling services as the company positions itself as a leader in the emerging field of antibody reactome analysis.
